ADC Therapeutics' IFRS loss for 9M 2021 was $195.645 million, up 2.8% from $190.361 million in the prior year. Revenue was $16.907 million. A year earlier company did not receive revenue.
Warning BlackTerminal uses cookies in order to personalize and improve the usability of the service. If you do not want to use cookies, please change your browser settings. Accept